Myonex Inc has applied for registration as an importer of specific controlled substances, according to a notice from the Drug Enforcement Administration (DEA). The substances are intended for use in clinical trials, research, and analytical purposes, and not for commercial sale of finished dosage forms. Interested parties have until March 29, 2021, to submit written comments or objections, or to request a hearing regarding this application. Written submissions should be directed to the DEA at their office in Springfield, Virginia.
Simple Explanation
Myonex Inc wants to bring in some special medicines from other countries to use in experiments and tests but not to sell them in stores. If anyone has questions or concerns, they can tell the people in charge by March 29, 2021.